Cargando…
P1469: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK OFF-TREATMENT PERIOD (WASHOUT) IN THE PHASE 3 CADENZA STUDY
Autores principales: | Röth, Alexander, Berentsen, Sigbjørn, Barcellini, Wilma, D’sa, Shirley, Jilma, Bernd, Michel, Marc, Weitz, Ilene C, Yamaguchi, Masaki, Nishimura, Jun-Ichi, Vos, Josephine, Cid, Joan, Storek, Michael, Wong, Nancy, Yoo, Ronnie, Jayawardene, Deepthi, Kralova, Katarina, Wardęcki, Marek, Shafer, Frank, Lee, Michelle, Broome, Catherine M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429917/ http://dx.doi.org/10.1097/01.HS9.0000972760.33312.35 |
Ejemplares similares
-
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
por: Röth, Alexander, et al.
Publicado: (2022) -
P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY
por: Röth, Alexander, et al.
Publicado: (2023) -
P1675: SUTIMLIMAB PROVIDES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH COLD AGGLUTININ DISEASE: OPEN-LABEL EXTENSION OF THE PHASE 3 CADENZA STUDY
por: Röth, Alexander, et al.
Publicado: (2023) -
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up
por: Röth, Alexander, et al.
Publicado: (2023) -
P1486: SERUM BIOMARKERS AS PREDICTORS OF RESPONSE TO SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): A POST-HOC ANALYSIS OF PHASE 3 CARDINAL AND CADENZA STUDY DATA
por: Barcellini, Wilma, et al.
Publicado: (2023)